The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers
Open accessAbstract
The active acquisition of epigenetic changes is a poorly understood but important process in development, differentiation, and disease. Our work has shown that repression of the p16/pRb pathway in human epithelial cells, a condition common to stem cells and many tumor cells, induces dynamic epigenetic remodeling resulting in the targeted methylation of a selected group of CpG islands. We hypothesized that cells in this epigenetically plastic state could be programmed by the microenvironment to acquire epigenetic changes associated with tumorigenesis. Here, we describe an in vitro model system where epigenetically plastic cells were placed in an environment that induced epithelial to mesenchymal transition (EMT) and led to a program of acquired de novo DNA methylation at targeted sites. In this model, we found that repression of E-cadherin transcription preceded the subsequent acquisition of methylated CpG sites. Furthermore, the induction of EMT was accompanied by de novo methylation of several other gene promoters, including those of the estrogen receptor and Twist. These data demonstrate that signals from the microenvironment can induce phenotypic and gene expression changes associated with targeted de novo epigenetic alterations important in tumor progression, and that these alterations occur through a deterministic, rather than stochastic, mechanism. Given the dynamic epigenetic reprogramming that occurs in these cells, DNA methylation profiles observed in human tumors may reflect the history of environmental exposures during the genesis of a tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“Thus, during cancer progression, one may envision that tumor cells can acquire epigenetic plasticity through repression of the p16/pRb pathway via mutations, deletions, or methylation (2), which then provides the potential for programming epigenetic events.”
Background
Cited by
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
“Recent data in mammary epithelial cells demonstrates that sustained activation of EMT leads to progressive epigenetic alterations in cells, inducing heritable effects that maintain the mesenchymal state even after EMT-initiating signals are no longer presen”
BackgroundBiomarkers for epithelial-mesenchymal transitions
Zeisberg, M., & Neilson, E. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36183 · Cited by 2,299
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869
Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 814
The Ins and Outs of the Epithelial to Mesenchymal Transition in Health and Disease
Nieto, M. A. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154036 · Cited by 720
Armstrong, A. J., Marengo, M. S., Oltean, S., Kemeny, G., Bitting, R. L., Turnbull, J. D., Herold, C. I., Marcom, P. K., George, D. J., & Garcia-Blanco, M. A. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0490 · Cited by 646
Gregory, P. A., Bracken, C. P., Smith, E., Bert, A. G., Wright, J. A., Roslan, S., Morris, M., Wyatt, L., Farshid, G., Lim, Y.-Y., et al. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-02-0103 · Cited by 552
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3870 · Cited by 474
Controversies around epithelial–mesenchymal plasticity in cancer metastasis
Williams, E. D., Gao, D., Redfern, A., & Thompson, E. W. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0213-x · Cited by 451
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
Epithelial-Mesenchymal Transition and Cell Cooperativity in Metastasis
Tsuji, T., Ibaragi, S., & Hu, G.-F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1618 · Cited by 413
Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition
McDonald, O. G., Wu, H., Timp, W., Doi, A., & Feinberg, A. P. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2084 · Cited by 379
Davalos, V, Moutinho, C., Villanueva, A., Boque, R., Silva, P., Carneiro, F., & Esteller, M. (2012) · Oncogene · doi:10.1038/onc.2011.383 · Cited by 351
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & De Maria, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 342
Epigenetic drivers of tumourigenesis and cancer metastasis
Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.004 · Cited by 328
Epithelial to mesenchymal transition and breast cancer
Tomaskovic-Crook, E., Thompson, E. W., & Thiery, J. P. (2009) · Breast Cancer Research · doi:10.1186/bcr2416 · Cited by 318
Mechanisms of the Epithelial–Mesenchymal Transition by TGF-β
Wendt, M. K., Allington, T. M., & Schiemann, W. P. (2009) · Future Oncology · doi:10.2217/fon.09.90 · Cited by 317
Blick, T., Hugo, H., Widodo, E., Waltham, M., Pinto, C., Mani, S. A., Weinberg, R. A., Neve, R. M., Lenburg, M. E., & Thompson, E. W. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9175-z · Cited by 292
Epithelial-mesenchymal transition in glioblastoma progression
IWADATE, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4113 · Cited by 288
Mechanisms of TGFβ-Induced Epithelial–Mesenchymal Transition
Moustakas, A., & Heldin, C.-H. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5070063 · Cited by 267
Eades, G., Yao, Y., Yang, M., Zhang, Y., Chumsri, S., & Zhou, Q. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229401 · Cited by 263
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
Mudduluru, G., Ceppi, P., Kumarswamy, R., Scagliotti, G. V., Papotti, M., & Allgayer, H. (2011) · Oncogene · doi:10.1038/onc.2011.13 · Cited by 252
Cannito, S., Novo, E., di Bonzo, L. V., Busletta, C., Colombatto, S., & Parola, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2737 · Cited by 239
Dumont, N., Liu, B., DeFilippis, R. A., Chang, H., Rabban, J. T., Karnezis, A. N., Tjoe, J. A., Marx, J., Parvin, B., & Tlsty, T. D. (2013) · Neoplasia · doi:10.1593/neo.121950 · Cited by 192
Self-citationRegulation of Stem Cell Plasticity: Mechanisms and Relevance to Tissue Biology and Cancer
Strauss, R., Hamerlik, P., Lieber, A., & Bartek, J. (2012) · Molecular Therapy · doi:10.1038/mt.2012.2 · Cited by 41
Metadata
- Authors
- Dumont, N., Wilson, M. B., Crawford, Y. G., Reynolds, P. A., Sigaroudinia, M., & Tlsty, T. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-09-30
- Volume
- 105
- Issue
- 39
- Pages
- 14867-14872
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2156927848
- Cited by
- 210
- References
- 1
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.